VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. The company is headquartered in San Diego, California.
| Revenue (TTM) | 131,000 |
| Gross Profit (TTM) | $-4.06M |
| EBITDA | $-11.27M |
| Operating Margin | -7967.00% |
| Return on Equity | -294.70% |
| Return on Assets | -65.20% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $1.70 |
| Price-to-Book | 0.54 |
| Price-to-Sales (TTM) | 10.19 |
| EV/Revenue | 1.181 |
| EV/EBITDA | -0.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -21.60% |
| Shares Outstanding | $3.49M |
| Float | $3.18M |
| % Insiders | 2.70% |
| % Institutions | 1.66% |
Volatility is currently expanding
Initial customer wins bring VivoSim's human-relevant liver and GI testing to the world's second-largest pharmaceutical market Initial customer wins bring VivoSim's human-relevant liver and GI testing to the world's second-largest pharmaceutical market
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 4,705,883 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,705,883 shares of common stock at an effective combined price of $0.85 per share and accompanying common warrant for aggregate gross proceeds of approximately $4.0 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.85 per share, will become exercisable immediately following receipt of shareholder approval and will expire five years from the initial exercise date.
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a $5 million payment from Eli Lilly.
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)
VivoSim's NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results VivoSim's NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VIVS and any ticker you trade — then tracks every position and per-strategy win rate.
